<DOC>
	<DOC>NCT02882425</DOC>
	<brief_summary>The primary purpose of this phase 1 study is to investigate the absolute bio-availability of a single oral dose of selexipag, i.e., to assess the amount of selexipag which reaches the blood when administered as an oral tablet (ACT-293987) compared to an intravenous administration in healthy subjects.</brief_summary>
	<brief_title>Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects</brief_title>
	<detailed_description>A pilot phase was conducted in 3 male subjects before the main phase for assessment of absolute bio-availability conducted in 16 other male subjects. The pilot phase aimed to determine the intravenous dose to be used in the main phase based on safety data and pharmacokinetics data.</detailed_description>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Signed informed consent prior to any studymandated procedure Aged from 18 to 45 (inclusive) at screening Body mass index (BMI) from 18.0 to 28.0 kg/m2 (inclusive) at screening Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests Any contraindication to the study drug formulations History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>selexipag</keyword>
	<keyword>bioavailability</keyword>
</DOC>